Table 3.
Influence of the type of kit administered, gender and age on uptake and true positive rates.
| Participation rates (%) | ||||||
|---|---|---|---|---|---|---|
| Factor | AME | CI | p-Value | |||
| Female | 6,8 | (5.9/7.6) | 0.000 | |||
|
Males |
Females |
|||||
| Factor | AME | CI | p-Value | AME | CI | p-Value |
| Kit | 2.6 | (-5.1/10.2) | 0.513 | 2.4 | (-4.8/9.6) | 0.512 |
| Age (55–59) | 6.2 | (3.8/8.7) | 0.000 | 6.7 | (5.9/13.3) | 0.000 |
| Age (60–64) | 11.2 | (8.5/13.9) | 0.000 | 9.6 | (5.9/13.3) | 0.000 |
| Age (65–69) | 10.7 | (6.2/15.1) | 0.000 | 5.1 | (1.9/8.3) | 0.002 |
|
True positive rates | ||||||
| Factor | AME | CI | p-Value | |||
| Female | -18.3 | (-22.1/-14.6) | 0.000 | |||
|
Males |
Females |
|||||
| Factor | AME | CI | p-Value | AME | CI | p-Value |
| Kit | 4.1 | (-0.4/8.6) | 0.074 | 4.4 | (-4.9/13.8) | 0.354 |
| Age (55–59) | 9.4 | (3.5/15.4) | 0.002 | -3.5 | (-11.7/4.7) | 0.402 |
| Age (60–64) | 16.1 | (11.7/20.6) | 0.000 | -1.7 | (-3.6/0.3) | 0.096 |
| Age (65–69) | 19.6 | (11.4/27.7) | 0.000 | -2.0 | (-12.8/8.9) | 0.721 |
Results are presented separately for men and women as there was evidence of interaction between gender and age. AME, average marginal effects; CI, 95% confidence intervals. Reference groups are males and 50–54 years age group.